In the end-stages of CKD, FGF23 could not reduce serum phosphate and it seems that abnormally high plasma levels of FGF23 cause adverse effects such as LVH, rapid progression of CKD and early mortality (12). This evidence concerns the gene FGF23 and chronic kidney disease.